Hair cloning in 2026: clinical and preclinical development status
Cell-based rejuvenation has entered early human studies. Dependable creation of new follicles remains preclinical.
Read analysis →Independent evidence tracker
Hair cloning trials, companies and evidence.
Hair Cloning Intelligence monitors companies, clinical studies and published evidence relevant to the development of human hair-follicle regeneration.
Current assessmentChecked 27 Oct 2026
Early clinical
Cell-based follicle rejuvenation has reached early human testing. Reliable creation of abundant new follicles is not an approved treatment.
6programs tracked
3key human studies
0approved cloning therapies
Weeklyevidence review
Evidence overview
Current research and clinical development
Three technologies described as “hair cloning”
Rejuvenation, multiplication and de novo regeneration have different biological objectives and evidence requirements.
Read analysis →Evaluating claims in hair-regeneration research
An evidence framework for distinguishing experimental findings from clinically available treatments.
Read analysis →Terminology
The term “hair cloning” covers several distinct technologies.
01
Follicle rejuvenation
Cultured cells are injected with the aim of restoring miniaturising follicles.
02
Follicle multiplication
A small donor sample is expanded to create a larger supply of transplantable follicular units.
03
De novo regeneration
New, cycling follicles are engineered from cells—the ambitious endpoint most people mean by cloning.
Clinical and practical context
Availability, cost and comparison with established treatment
Evidence-based guide
When will hair cloning be available? Trial dates and evidence
Human follicular-cell trials are under way, including EPI-001, but current evidence does not support a date for an approved, widely available hair-cloning treatment.
Read the answer →Evidence-based guide
Hair cloning cost in 2026: what is known and unknown
No approved routine hair-cloning treatment or established price exists. Future cost depends on cell manufacturing, quality control, implantation, scale and durability.
Read the answer →Evidence-based guide
Hair cloning and hair transplantation: implications for donor supply
A transplant redistributes existing resistant follicles. Follicle multiplication aims to expand the supply and remains experimental.
Read the answer →Development map
Development status in October 2026
GoalCurrent evidenceOur assessment
Rejuvenate existing folliclesRegistered and company-reported early human testingEarly clinical
Multiply donor potentialHistorical human studies; no approved scalable productClinical evidence, unresolved path
Create net-new folliclesLaboratory and preclinical systemsPreclinical
Assessment reflects publicly traceable evidence, not projected launch dates. Sources were checked on 27 October 2026; the latest company-reported milestones did not change any evidence-stage classification.